Skip to content
2000
Volume 3, Issue 2
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Fibromyalgia syndrome is not a diagnosis in itself, but merely represents a set of classification criteria. It is possible to distinguish between different subgroups. Such a distinction can be made on the basis of psychopathological, clinical and laboratory tests. One subgroup reveals elevated level of different cytokines. The treatment of primary fibromyalgia can be optimized by taking these subgroups into consideration since one group responds better to 5-HT3 receptor antagonists, whereas another benefits more from antidepressants and a third group from psychotherapy. In socalled secondary fibromyalgia, 5-HT3 receptor antagonists may be used in the attempt to manage pain that might still persist after treatment of the primary disease.

Loading

Article metrics loading...

/content/journals/crr/10.2174/157339707780619386
2007-05-01
2025-05-25
Loading full text...

Full text loading...

/content/journals/crr/10.2174/157339707780619386
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test